Navigation Links
Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
Date:1/18/2013

THOUSAND OAKS, Calif., Jan. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its fourth quarter and full year 2012 financial results on Wednesday, Jan. 23, 2013, after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Standard Time. Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 30 days after the event.  

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss , 805-313-6151 (media)
Arvind Sood , 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
2. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
3. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
4. Amgen Announces 2012 Third Quarter Dividend
5. Amgen to Present at the Leerink Swann Global Healthcare Conference
6. Amgen to Acquire Micromet
7. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
10. Amgen Announces 2012 First Quarter Dividend
11. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016  Vyriad Inc. announced today the ... company,s Board of Directors. "We are delighted ... our business and develop our oncolytic viruses as the ... Stephen Russell , MD, PhD, CEO of Vyriad. ... our vision and passion for making a difference for ...
(Date:12/7/2016)... DIEGO , December 7, 2016 ... in the International Journal of Molecular Sciences a team of ... 1 ] have demonstrated that expression of NR2F6 ...  These scientists tested for NR2F6 in patient,s cervical cancer tissue ... their tumors. "This is an interesting study and ...
(Date:12/7/2016)... , ... December 07, 2016 ... ... opening applications to an early access program for SmartBiome -- a novel ... with the simultaneous specific enrichment and detection of hundreds of different genes. ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... largest privately-held contract pharmaceutical development and manufacturing organisation, today announced the ... company combining a leading CRO and the industry’s only Contract Commercial Organization ...
Breaking Biology Technology:
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/22/2016)... -- According to the new market research report "Biometric System ... Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and ... expected to grow from USD 10.74 Billion in 2015 to reach USD ... 2022. Continue Reading ... ...
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
Breaking Biology News(10 mins):